Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13154968 | 0.82 | ALDH1A1 (0.62) | LMNAALDH1A1KDM4ETP53MAPT | |
| SCHEMBL14593916 | 0.80 | SLC2A1 (0.53) | ALDH1A1KDM4ETP53MAPTHSD17B10 | |
| SCHEMBL20226528 | 0.78 | LMNA (0.46) | LMNAALDH1A1KDM4ETP53MAPT | |
| SCHEMBL125543 | 0.78 | ALDH1A3 (0.64) | LMNAALDH1A1TP53ALDH1A3KMT2A | |
| SCHEMBL12369341 | 0.76 | RXRA (0.41) | ALDH1A1KDM4EKMT2AGAA | |
| SCHEMBL18782830 | 0.75 | ALDH1A3 (0.47) | LMNAALDH1A1KDM4ETP53MAPT | |
| SCHEMBL17854032 | 0.75 | ALDH1A1 (0.44) | LMNAALDH1A1KDM4ETP53MAPT | |
| SCHEMBL19002846 | 0.75 | NQO1 (0.56) | LMNAALDH1A1KDM4ETP53MAPT | |
| SCHEMBL15148197 | 0.74 | ALDH1A1 (0.61) | ALDH1A1KDM4ETP53MAPTHSD17B10 | |
| SCHEMBL21340775 | 0.74 | SLC6A4 (0.45) | ALDH1A1MAPTTUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246141-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2021-08-12 | — | — | US | disclosed |
| US-10858361-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200255431-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-08-13 | — | — | US | disclosed |
| US-10689386-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190276457-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2019-09-12 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8673954-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8507522-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8242156-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | LMNA 3064/4885ALDH1A1 201/4885KDM4E 553/4885 |
| US-10858361-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | RB1, RRM2, RRM2B | LMNA 3789/4885ALDH1A1 606/4885KDM4E 3029/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | LMNA 3064/4885ALDH1A1 201/4885KDM4E 553/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | LMNA 2800/4885ALDH1A1 365/4885KDM4E 1193/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | LMNA 3064/4885ALDH1A1 201/4885KDM4E 553/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | LMNA 2724/4885ALDH1A1 287/4885KDM4E 571/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | LMNA 2786/4885ALDH1A1 132/4885KDM4E 437/4885 |
| US-20210246141-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | RB1, RRM2, RRM2B | LMNA 3789/4885ALDH1A1 606/4885KDM4E 3029/4885 |
| US-20190276457-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | DPYD, TP53, TYMP | LMNA 4282/4885ALDH1A1 620/4885KDM4E 3080/4885 |
| US-10689386-B2 | Pyrazolo[4,3-d]pyrimidines as antitumor agents | DPYD, TP53, TYMP | LMNA 4282/4885ALDH1A1 620/4885KDM4E 3080/4885 |
| US-20200255431-A1 | Pyrazolo[4,3-d]pyrimidines as Antitumor Agents | RB1, RRM2, RRM2B | LMNA 3789/4885ALDH1A1 606/4885KDM4E 3029/4885 |
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | LMNA 3064/4885ALDH1A1 201/4885KDM4E 553/4885 |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | LMNA 3064/4885ALDH1A1 201/4885KDM4E 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.